Diagnostic Products Corp.
This article was originally published in The Gray Sheet
Executive Summary
President Sidnew Aroesty resigns "for personal reasons," effective Sept. 30, the company says. Aroesty, a 17-year veteran of DPC, will continue to serve on the board and will act as a consultant to the firm. He will be succeeded by Michael Ziering, who most recently served as the firm's vice president of administration. In addition, Aroesty has resigned as president of Cirrus Diagnostics, DPC's wholly owned subsidiary. Douglas Olsen, VP and executive VP for Cirrus, will take over the position
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.